Asthalin: Fast-Acting Relief for Acute Bronchospasm
| Product dosage: 100mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 1 | $50.20 | $50.20 (0%) | 🛒 Add to cart |
| 2 | $35.14 | $100.40 $70.28 (30%) | 🛒 Add to cart |
| 3 | $30.12 | $150.60 $90.36 (40%) | 🛒 Add to cart |
| 4 | $27.61 | $200.80 $110.44 (45%) | 🛒 Add to cart |
| 5 | $26.10 | $251.00 $130.52 (48%) | 🛒 Add to cart |
| 6 | $25.10 | $301.20 $150.60 (50%) | 🛒 Add to cart |
| 7 | $23.67 | $351.39 $165.66 (53%) | 🛒 Add to cart |
| 8 | $23.22 | $401.59 $185.74 (54%) | 🛒 Add to cart |
| 9 | $22.31 | $451.79 $200.80 (56%) | 🛒 Add to cart |
| 10 | $21.59
Best per inhaler | $501.99 $215.86 (57%) | 🛒 Add to cart |
Synonyms | |||
Asthalin (salbutamol sulfate) is a rapid-onset, short-acting beta-2 adrenergic agonist bronchodilator indicated for the treatment and prevention of bronchospasm in patients with reversible obstructive airway disease, including asthma and chronic obstructive pulmonary disease (COPD). Its primary mechanism of action involves selective stimulation of beta-2 adrenergic receptors in bronchial smooth muscle, resulting in relaxation and dilation of the airways. This facilitates improved airflow, reduces wheezing, and alleviates shortness of breath, making it a cornerstone medication in both rescue and maintenance therapy protocols. Available in multiple formulations—including metered-dose inhalers (MDI), dry powder inhalers (DPI), nebulizer solutions, and tablets—Asthalin offers flexibility in administration tailored to patient needs, age, and severity of condition.
Features
- Contains salbutamol sulfate as the active pharmaceutical ingredient
- Available in multiple formulations: MDI (100 mcg/puff), DPI (200 mcg/dose), nebulization solution (1mg/mL, 2.5mg/2.5mL, 5mg/2.5mL), and oral tablets (2mg, 4mg)
- Rapid onset of action: bronchodilation typically begins within 5 minutes when inhaled
- Duration of effect: 4 to 6 hours for inhaled forms
- Portable and easy-to-use delivery systems, especially press-and-breathe inhalers
- Compatible with spacer devices for improved lung deposition and ease of use, particularly in pediatric and elderly populations
Benefits
- Provides rapid relief from acute asthma attacks and exercise-induced bronchospasm
- Improves lung function parameters, including forced expiratory volume in 1 second (FEV1) and peak expiratory flow rate (PEFR)
- Reduces the frequency and severity of asthma exacerbations when used as prescribed
- Enhances quality of life by enabling normal physical activity and reducing emergency department visits
- Supports flexible dosing regimens adaptable to individual patient response and clinical scenario
- May be used as a preventive agent prior to allergen exposure or strenuous exercise
Common use
Asthalin is commonly prescribed for the management of bronchospasm associated with asthma, COPD, bronchitis, and emphysema. It is also used prophylactically to prevent exercise-induced bronchoconstriction. In clinical practice, it serves as a first-line rescue medication during acute dyspnea episodes. Hospital settings frequently employ nebulized Asthalin for severe exacerbations. Beyond respiratory conditions, it is sometimes used off-label in obstetrics to suppress premature labor due to its tocolytic effects, though this application requires careful monitoring.
Dosage and direction
Dosage must be individualized based on patient age, severity of condition, and formulation. For adults using the MDI (100 mcg/puff), the typical rescue dose is 1–2 puffs every 4–6 hours as needed, not exceeding 8 puffs in 24 hours. For nebulization, 2.5 mg diluted in saline, administered 3–4 times daily. Pediatric dosing is weight-based: 0.1–0.15 mg/kg per nebulization dose (max 2.5 mg), or 1–2 puffs via MDI with spacer. Oral tablets: adults 2–4 mg three to four times daily; children 0.1–0.15 mg/kg per dose. Always shake the inhaler well before use. For inhalers, exhale fully, place mouthpiece in mouth, inhale deeply while pressing canister, hold breath for 10 seconds, then exhale slowly. Wait 1 minute between puffs. Rinse mouth after steroid-containing combinations to prevent oral candidiasis.
Precautions
Use with caution in patients with cardiovascular disorders (hypertension, arrhythmias, ischemic heart disease), diabetes mellitus, hyperthyroidism, or hypokalemia. Monitor serum potassium levels periodically, as beta-2 agonists can cause transient hypokalemia. Excessive use may lead to paradoxical bronchospasm or loss of effectiveness—seek medical advice if response decreases. Not recommended as sole therapy for severe or unstable asthma. In elderly patients, consider increased sensitivity to beta-agonist effects. Pregnancy Category C: use only if potential benefit justifies potential risk. Avoid abrupt discontinuation.
Contraindications
Hypersensitivity to salbutamol or any component of the formulation. Tachyarrhythmias. Severe cardiac disease uncontrolled with medication. Not advised in patients with known or suspected pheochromocytoma. Contraindicated with non-selective beta-blockers (e.g., propranolol), which may antagonize effects.
Possible side effect
Common: tremor, headache, tachycardia, palpitations, muscle cramps, nervousness. Less common: hypokalemia, hyperglycemia, dizziness, throat irritation, cough. Rare: paradoxical bronchospasm, allergic reactions (rash, angioedema), chest pain, arrhythmias. Most side effects are dose-dependent and transient.
Drug interaction
Beta-blockers (e.g., propranolol) may antagonize bronchodilator effect and increase risk of bronchospasm. Concomitant use with other sympathomimetics may potentiate cardiovascular effects. Diuretics or corticosteroids may enhance hypokalemic effect. MAO inhibitors and tricyclic antidepressants may potentiate vascular effects. Use cautiously with digoxin—risk of hypokalemia may increase digoxin toxicity. Theophylline may increase risk of adverse effects.
Missed dose
If a scheduled dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose to catch up. For rescue use, take as needed—no fixed schedule applies.
Overdose
Symptoms may include angina, hypertension or hypotension, tachycardia, arrhythmias, nervousness, headache, tremor, dry mouth, palpitations, nausea, hypokalemia, hyperglycemia. Cardiac arrest may occur in severe cases. Treatment is supportive and symptomatic: discontinuation, cardiac monitoring, correction of electrolytes. Consider cardioselective beta-blocker (e.g., metoprolol) if severe cardiovascular symptoms occur, but with caution in asthmatics due to risk of bronchospasm.
Storage
Store at room temperature (15–30°C). Avoid freezing, direct sunlight, and excessive heat. Do not puncture or incinerate the canister. Keep away from children. For nebulization solutions, check clarity and discard if discolored or contaminated. MDIs should be cleaned weekly; follow manufacturer instructions.
Disclaimer
This information is for educational purposes and does not replace professional medical advice. Always consult a healthcare provider for diagnosis, treatment decisions, and personalized dosing. Do not initiate, modify, or discontinue therapy without medical supervision. Not all uses, precautions, or interactions are listed here.
Reviews
Clinical studies and meta-analyses consistently demonstrate Asthalin’s efficacy in rapidly reversing bronchoconstriction. A 2022 systematic review noted onset of action within 5 minutes in 90% of patients, with mean FEV1 improvement of 30–35% post-inhalation. Long-term safety profiles are well-established, though overuse remains a concern. Patient satisfaction surveys highlight portability and rapid symptom relief as key advantages. Some critiques note the short duration requires frequent dosing in persistent cases, making combination with long-acting agents preferable for maintenance. Overall, it remains a gold-standard rescue therapy in global asthma guidelines.